Updated NETs Clinical Trials

1. Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

   Conditions: Tumor-associated Hyperinsulinism (Tumor HI) Interventions: Drug: Ersodetug (9 mg/kg) + SOC Sponsors: Rezolute Available

2. Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program

   Conditions: Neuroendocrine (NE) Tumors; Oral Anti-Tumor Drugs; Therapeutic Education Program Interventions: Other: Questionnaires Sponsors: Hospices Civils de Lyon Not yet recruiting

3. Stress and Anxiety Effects on Valuation

   Conditions: Value Adaptation Interventions: Behavioral: Socially Evaluated Cold Pressor Task (SECPT); Behavioral: Non-Stressful Control Task Sponsors: NYU Langone Health Not yet recruiting

4. Impact of Funcional Exercise and Supplementation in Perimenopausal Women's Health

   Conditions: Perimenopause; Aging Interventions: Dietary Supplement: Exercise + nutritional supplement; Dietary Supplement: Exercise + placebo supplement Sponsors: University of Valencia Recruiting

5. A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma

   Conditions: Uterine Cervical Neoplasms Interventions: Other: Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma. Sponsors: Lili; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Cancer Research Institute of Zhongshan City; The First Affiliated Hospital of Zhengzhou University; Qilu Hospital of Shandong University; Fujian Province Tumor Hospital; Fujian Maternity and Child Health Hospital; Zhejiang Cancer Hospital; The Third Affiliated Hospital of Kunming Medical College.; Obstetrics & Gynecology Hospital of Fudan University; Women's Hospital School Of Medicine Zhejiang University; National Cancer Center/National Cancer Clinical Medical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Peking Union Medical College Hospital; The Affiliated Tumor Hospital of Xinjiang Medical University; The First Affiliated Hospital of Anhui Medical University; Tianjin Medical University Cancer Institute and Hospital; Renmin Hospital of Wuhan University Not yet recruiting

6. Memantine Hydrochloride in Prostate Cancer Patients

   Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer; Neuroendocrine Prostate Cancer (NEPC) Interventions: Drug: Memantine Hydrochloride Sponsors: Bin Xu; The First People's Hospital of Lianyungang Not yet recruiting

7. A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

   Conditions: SST2-positive Neuroendocrine Neoplasms; Neuroendocrine Tumors; Neuroendocrine Neoplasm Interventions: Drug: CRN09682 Sponsors: Crinetics Pharmaceuticals Inc. Recruiting

8. DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

   Conditions: Lung Neoplasms Sponsors: AstraZeneca Not yet recruiting

9. Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

   Conditions: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor Interventions: Drug: Paltusotine; Drug: Placebo Sponsors: Crinetics Pharmaceuticals Inc. Recruiting

10. CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

    Conditions: Medulloblastoma Sponsors: St. Jude Children's Research Hospital Recruiting

11. Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

    Conditions: Metastatic/Locally Advanced Small-Cell Lung Cancer; Metastatic/Locally Advanced Poorly Differentiated NEC; Metastatic/Locally Advanced High-grade MTC Interventions: Drug: Tarlatamab Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; Amgen Recruiting

12. Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

    Conditions: Small Cell Lung Carcinoma; Large Cell Neuroendocrine Carcinoma of the Lung; Neuroendocrine Prostate Cancer; Gastroenteropancreatic Neuroendocrine Carcinoma Interventions: Drug: 225Ac-ETN029; Drug: 111In-ETN029 Sponsors: Novartis Pharmaceuticals Recruiting

13. A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

    Conditions: Neuroendocrine Tumor of the Lung; Neuroendocrine Carcinoma of Lung; Neuroendocrine Carcinoma; Neuroendocrine Carcinoma of Prostate Interventions: Diagnostic Test: PET/CT; Biological: 177Lu-DTPA-SC16.56 Sponsors: Memorial Sloan Kettering Cancer Center Not yet recruiting

14. Vasopressin in the Elderly: Physiological Changes in Neuroendocrine Function and Urinary Secretion in Healthy Aging

    Conditions: Healthy Ageing Interventions: Other: Hypertonic 3% saline; Other: Water Sponsors: University Hospital, Basel, Switzerland Completed

15. Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

    Conditions: High Grade Neuroendocrine Neoplasms Interventions: Drug: Zanzalintinib Sponsors: Washington University School of Medicine; Exelixis Not yet recruiting

16. Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

    Conditions: Intestinal Neuroendocrine Tumor Interventions: Other: Additional blood tests (CRP and serum albumin) and data collection. Sponsors: Institut Claudius Regaud Recruiting

17. Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

    Conditions: Advanced Solid Tumors Interventions: Drug: MB0151 for injection Sponsors: Mainline Biosciences (Shanghai) Co., Ltd Recruiting

18. Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

    Conditions: Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Interventions: Radiation: [177Lu]Lu-DOTA-TATE; Drug: Octreotide LAR Sponsors: Novartis Pharmaceuticals Recruiting

19. Behavioral Therapy for Crohn's Disease

    Conditions: Crohn's Disease Interventions: Behavioral: Primary Intervention for Combination Therapy - IBD Coping Strategies Program; Behavioral: Time and Attention Control - IBD Support Program Sponsors: Icahn School of Medicine at Mount Sinai; The Leona M. and Harry B. Helmsley Charitable Trust Recruiting

20. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

    Conditions: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma; Pheochromocytoma/Paraganglioma (PPGL); Pancreatic Ductal Adenocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Gastric Cancer; Cholangiocarcinoma; Bladder Cancer Interventions: Drug: [18F]FAPI-74; Drug: [18F]FDG Sponsors: National Cancer Institute (NCI) Recruiting

21. NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

    Conditions: Non-squamous Metastatic Non-Small-Cell Lung Carcinoma Sponsors: AstraZeneca Recruiting

22. [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

    Conditions: Head and Neck Tumors; Kidney Cancers; Small Cell Lung Cancers; Pheochromocytoma/Paragangliomas; Gastrointestinal Neuroendocrine Tumors; Somatostatin Receptor Positive Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Recruiting

23. Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

    Conditions: Somatostatin Receptor Positive; Gastrointestinal Neuroendocrine Tumors; Pheochromocytoma; Paragangliomas Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Recruiting

24. A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

    Conditions: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Etoposide Sponsors: National Cancer Institute (NCI) Recruiting

25. Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

    Conditions: Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma; Soft Tissue Sarcoma; Small Bowel Adenocarcinoma; Duodenum Adenocarcinoma; Gastric Adenocarcinoma Interventions: Drug: Dostarlimab; Drug: Chemotherapy Sponsors: UNICANCER; National Cancer Institute, France; GlaxoSmithKline Recruiting

26. Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

    Conditions: Small Cell Lung Cancer; Neuroendocrine Cancer Interventions: Biological: ZG006 Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Recruiting

27. Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

    Conditions: Small Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract Interventions: Drug: Lurbinectedin; Drug: Avelumab Sponsors: National Cancer Institute (NCI) Recruiting

28. Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

    Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Recruiting

29. DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

    Conditions: Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin Sponsors: Boehringer Ingelheim Recruiting

30. Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

    Conditions: Advanced Prostate Cancer; Metastatic Prostate Cancer; Metastatic Prostate Neuroendocrine Carcinoma Interventions: Drug: 18F-fluciclovine; Device: PET/CT Sponsors: Brigham and Women's Hospital; Blue Earth Diagnostics Recruiting

31. Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

    Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma; Unresectable Merkel Cell Carcinoma Interventions: Drug: Avelumab; Procedure: Biopsy Procedure; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Tuvusertib Sponsors: National Cancer Institute (NCI) Active, not recruiting

32. Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

    Conditions: Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms Interventions: Drug: 177Lu-edotreotide; Drug: Everolimus Sponsors: Grupo Espanol de Tumores Neuroendocrinos; ITM Oncologics GmbH; MFAR Recruiting

33. DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

    Conditions: Small Cell Lung Carcinoma; Neuroendocrine Neoplasms; Extra-pulmonary Neuroendocrine Carcinoma Interventions: Drug: BI 764532, dose 1; Drug: BI 764532, dose 2 Sponsors: Boehringer Ingelheim Recruiting

34. Paraphilic Disorders and Other Conditions With Risk for Sexual Violence: a Case-control Study

    Conditions: Paraphilic Disorders; Sexual Addiction; Parasomnia Interventions: Behavioral: Treatment as usual Sponsors: Region Stockholm; Umeå University Recruiting

35. Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors

    Conditions: Pancreatic Neuroendocrine Tumor; Solid Pancreatic Neoplasms Interventions: Diagnostic Test: Blood collection Sponsors: Fudan University Recruiting

36. Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

    Conditions: Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Digestive System Neuroendocrine Tumor G2; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Digestive System Neuroendocrine Tumor G2 Interventions: Procedure: Biospecimen Collection; Drug: Cabozantinib; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Sunitinib Sponsors: National Cancer Institute (NCI) Recruiting

37. Potential Benefits of the Somatic Psychoeducational Intervention

    Conditions: Work Related Stress Interventions: Behavioral: Somatic Psychoeducational Intervention Sponsors: University of Florida Completed

38. Oxytocin Effects on Bone in Children With Autism Spectrum Disorder

    Conditions: Autism Spectrum Disorder; Bone Health Interventions: Drug: 1. Intranasal oxytocin spray; Drug: 2. Intranasal placebo spray; Drug: 3. Intranasal Oxytocin spray Sponsors: Elizabeth Austen Lawson; United States Department of Defense; University of Virginia Recruiting

39. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

    Conditions: Metastatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine Sponsors: National Cancer Institute (NCI) Recruiting

40. Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep to Reward- and Stress-Related Brain Function

    Conditions: Depression in Adolescence Interventions: Behavioral: Sleep extension and advance; Behavioral: Regular sleep duration and timing Sponsors: University of Oregon; Oregon Research Institute; University of Pittsburgh; National Institute of Mental Health (NIMH) Recruiting

41. A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder

    Conditions: Binge-eating Disorder Interventions: Drug: TNX-1900 (Tonix Pharmaceuticals); Drug: Placebo Sponsors: Massachusetts General Hospital Recruiting

42. Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors Unresectable; Neuroendocrine Tumor Metastatic; Gastroenteropancreatic Neuroendocrine Tumor; Bronchial Neuroendocrine Tumor; Paraganglioma; Pheochromocytoma Interventions: Drug: [203Pb]VMT-α-NET; Drug: [212Pb]VMT-α-NET Sponsors: Perspective Therapeutics Recruiting

43. StableEyes With Active Neurofeedback

    Conditions: Vestibular Disorder; Vestibular Schwannoma; Space Motion Sickness; Motion Sickness Interventions: Behavioral: Traditional Therapy; Device: SWAN Sponsors: Johns Hopkins University; National Aeronautics and Space Administration (NASA) Recruiting

44. Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial

    Conditions: MEN1 Gene Mutation Interventions: Drug: Leflunomide 20 mg Sponsors: University Hospital, Basel, Switzerland Active, not recruiting

45. Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

    Conditions: Craniopharyngioma, Child; Craniopharyngioma; Recurrent Craniopharyngioma Interventions: Drug: Tovorafenib Sponsors: Sabine Mueller, MD, PhD; Day One Biopharmaceuticals, Inc. Recruiting

46. A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

    Conditions: Acromegaly; GEP-NET Interventions: Drug: Debio 4126; Drug: Sandostatin LAR; Drug: Somatuline ATG Sponsors: Debiopharm International SA Terminated

47. Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

    Conditions: Metastatic Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma; Neuroendocrine Tumors; Carcinoid Tumor Interventions: Drug: Cabozantinib; Drug: Nivolumab Sponsors: Fox Chase Cancer Center; Exelixis Recruiting

48. Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors Interventions: Diagnostic Test: 18F-DOPA with furosemide Sponsors: University of Alberta Active, not recruiting

49. Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

    Conditions: Neuroendocrine Tumors; Carcinoma, Neuroendocrine Sponsors: National Cancer Institute (NCI) Recruiting

50. Lutathera and ASTX727 in Neuroendocrine Tumours

    Conditions: Neuroendocrine Tumors Interventions: Drug: ASTX727; Radiation: Lutathera Sponsors: Imperial College London; Advanced Accelerator Applications Recruiting